British schoolgirl killed in Jamaica after family moved for safer life – Metro.co.uk

Caption: British schoolgirl fled London because of knife crime only to be stabbed in her parents native Jamaica (Picture: Mega)

A teenager who left London to live in Jamaica over fears of rising knife crime in the capital has been stabbed to death.

Stefika Smith, 17, left her Thornton Heath home in south London for a new start on the Caribbean Island because her parents Morris, 56, and Pauline, 54, wished she could have the same idyllic life growing up they did.

The star-student, whose killer has yet to be found, was murdered and dumped next to a lonely track beside a sugarcane field on May 12, two days after vanishing on a trip into town with a friend.

She was found wearing her favourite one-piece yellow body suit with a single stab wound to the throat in rural May Pen, in the south of the island, two weeks before her 18th birthday.

Her clothes were ripped and there were signs she had put up a struggle, authorities have said.

Stefikas body was found dumped near a sugarcane field (Picture: Mega)The familys trauma was made all the worse after a picture of Stefikas body was posted on social media, before they had learned she had been killed.

Speaking out for the first time about her daughters death, Pauline said: Ive lost an angel. There was a lot of knife crime in London and I wanted to take Stefika away from those dangers.

We wanted to her to have the same idyllic life my husband and I had growing up in Jamaica. But wicked people put an end to that.

My beautiful sweet daughter left what we saw as a knife threat but became a stabbing victim herself where we took her to be safer. I still cannot take it in.

Stefika, a pupil at Norbury Manor Business Enterprise College for Girls, sang at the gospel choir of the New Testament Church of God in Brixton before moving to Jamaica in May 2016.

Stefika left London in 2016 (Picture: The Mega Agency)Mum Pauline, who herself lived in Jamaica until she was 23, told the Sunday People: Stefika was always concerned about her safety in London when she went out because of the stabbings and gangs.

She didnt like to be on the streets. It stopped her meeting friends or joining groups.

By contrast, growing up in Jamaica in the 1960s was an ideal world. We could do anything totally safely.

There was no sense of danger. We could be outside all the time, swimming in rivers or playing in each others yards.

But crime in the region has soared since the family moved to the area with the government declaring a state of emergency in 2018.

During states of emergency police and military personnel are given the authority to search people and buildings, curtail business hours and detain individuals without a warrant.

Crime rates in Clarendon have soared with the govenment declaring a state of emergency (Picture: The Mega Agency)Prime Minister Andrew Holness announced that a one-month extension to the state of emergency in Clarendon, the district covering May Pen, will last until 19 October and said it could yet be extended further.

Under the emergency measures, businesses must close at 10pm each day.

Murder and shooting rates fell by 73 per cent between 5 September and 11 September as a result of the emergency state, police officials said.

They have recorded 948 murders and 908 shooting incidents across 19 police divisions since the start of 2019, with much of the violence linked to gang rivalries.

Read the rest here:

British schoolgirl killed in Jamaica after family moved for safer life - Metro.co.uk

Satoshi Nakamoto is Dead, Thinks BitMEX’s Arthur Hayes – Cryptonews

Source: iStock/D-Keine

Arthur Hayes, CEO of cryptocurrency exchange BitMEX, thinks that the Cryptoverses icon and the inventor of the worlds first and most popular cryptocurrency, Bitcoin, is in fact dead.

We dont know who Satoshi Nakamoto is, or even are, but the rumors about their identity, or if they are even still alive for that matter, have been a constant in the Cryptoverse since its inception. Many large figures within this industry have weighed in on the topic too. Just recently, when asked if well ever find out who Satoshi is, Bloomberg reports that BitMEXs co-founder replied with a no, explaining that: I think theyre already dead.

Some are saying that Harold Thomas Finney, cryptographer and crypto pioneer who worked closely with Satoshi Nakamoto, was Satoshi himself - Finney passed away in 2014 and was cryopreserved by the Alcor Life Extension Foundation.

Over the years, many have come out with various claims relating to the Bitcoin founder, but none are as interesting as those claiming to actually be him. The most famous case is that of a controversial Australian computer scientist and supporter of Bitcoin SV (BSV), Craig Wright, known also as Faketoshi. In the most recent episode of the long Faketoshi saga, Wright was ordered by the court to pay BTC 550,000 (USD 5.5 billion) to the brother of his late business partner David Kleiman, who sued Wright for stealing Kleiman's BTC holdings.

Watch the latest reports by Block TV.

In the meantime, we saw Caantoshi enter the scene, when a person called James Caan came out with a series of detailed blog posts, claiming to be the Bitcoin creator.

Going back to Hayes, though, speaking at the Milken Institute Asia Summit in Singapore, he stressed how Satoshi's creation is changing the global market: unlike the traditional markets which have an opening and closing times, as well as lunch and weekend breaks, the cryptocurrency market is opened 24/7/365. Hayes finds that digital finance will have an effect on every aspect of the market, including traditional equities, bond and currency trading, and that these traditional markets will absorb elements of the digital markets, probably costing traders their lunch breaks and weekends in the process, Bloomberg reported.

Hayes, who is known for his earlier predictions, now estimates that BTC will hit USD 20,000 in a year, and USD 100,000 in three years. He explained that one realizes that BTC is not such a strange idea, once one understand[s] that everything will be digital in the next 10 years. He added that crypto is not a threat to fiat and that itd be useful to the governments too, because they can track things better in their native currencies, which they cant do with physical cash.

Meanwhile, as reported in July, the U.S. Commodity Futures Trading Commission (CFTC) started an investigation into whether BitMEX broke rules by allowing Americans to trade on the platform, which isnt registered with the agency.

Read the original here:

Satoshi Nakamoto is Dead, Thinks BitMEX's Arthur Hayes - Cryptonews

FIT LIFE: 3 ways to release tension in your hamstrings – KY3

SPRINGFIELD, Mo. -- Tight hamstrings can lead to pain in your hips and lower back. So, on today's Fit Life we're visiting with Cady O'Quinn of Sumits Hot Yoga to look at three ways to stretch those hamstrings.

Here's how Cady described these Yoga moves:

From table top position (see video), extend your right leg back. On an exhale, bend the knee, squeezing heel to glutes, as though you want to crush a grape between your calf and hamstrings. Hold for a breath, repeat three times. Return the right leg to extension, flexing the right foot. Lower ball of the foot to the floor and gently press back into the heel, stretching the calf. Hold for five breaths, then relax. Repeat sequence on left side.

Sit on the floor, or prop your seat up with a folded blanket. Extend right leg out, bend left knee and bring left foot to the inside of your right thigh. Sit up tall, and contract your right quadriceps, flexing the right foot, release. Repeat twice more, holding the last contraction for three breaths. Relax right leg, point your navel toward your right knee, and fold over the leg. Hold five to 10 breaths. Roll up slowly. Repeat on left side.

Lie on your back. Knees bent, feet flat on the floor. Extend right leg to the ceiling. Wrap your hands around a towel or a strap around the back of your right thigh, keep shoulders and hips flush to the floor. Flex the right foot, and keep the right knee slightly bent (or very bent, if this is too challenging). Drive the right heel away from the center of your body, using the hands to create resistance. Hold for a count of five, and then relax the leg. Walk the hands/strap up higher and the leg, and repeat, using resistance. One final time, reach as high as you can, keeping the knee soft, and drive the heel away, hold for five seconds and then relax. Repeat this sequence on the left side.

Original post:

FIT LIFE: 3 ways to release tension in your hamstrings - KY3

If you see a spotted lanternfly, kill it – PennLive.com

If you see a spotted lanternfly an invasive species native to Asia that has spread to 14 counties in Pennsylvania since 2014 dont call the police. Its not something they can do anything about.

Kill it. Squash it, smash it. Just get rid of it, advises the Pennsylvania Department of Agriculture. These are called bad bugs for a reason. Dont let them take over your county next.

After youve dispatched the insect, you can report its presence online or by calling 1-888-4BADFLY.

The agency explains, The spotted lanternfly causes serious damage in trees, including oozing sap, wilting, leaf curling and tree dieback.

In addition to tree damage, when spotted lanternflies feed, they excrete a sugary substance, called honeydew, that encourages the growth of black sooty mold, which is harmless to people but causes damage to plants.

And, in counties infested and quarantined for the insect, residents report hundreds of the insects that affect their quality of life and ability to enjoy the outdoors during the spring and summer months. Spotted Lanternflies will cover trees, swarm in the air, and their honeydew can coat decks and play equipment.

After being discovered in Berks County in 2014, the insect has spread to 14 Pennsylvania counties, which are now under quarantine. Those counties are Berks, Bucks, Carbon, Chester, Dauphin, Delaware, Lancaster, Lebanon, Lehigh, Monroe, Montgomery, Northampton, Philadelphia and Schuylkill.

Infestations of the insect also have been found in Delaware, Maryland, New Jersey, New York and Virginia.

Spotted lanternflies are beginning to lay their eggs in masses of 30-50 eggs each, according to the department. They will continue through late November or early December.

The egg masses, which look like gray or tan, unevenly spread, smears of mortar or clay, will be deposited on any smooth trunked tree, stone or other flat smooth surface, including vehicles, campers, yard furniture, farm equipment or any other items stored outside.

The non-native, invasive spotted lanternfly passes through four stages of nymph development before becoming the winged adult.

In addition to killing all winged adults, the department encourages the destruction of every egg mass that is spotted. Simply scrape them off, double bag them and throw them in the garbage, or place them in alcohol or hand sanitizer.

Successful scrapings can be reported online.

Penn State Extension has developed additional instructions for homeowners wanting to attack their own spotted lanternfly problems. They advise the following.

Wrap tree trunks that the insects are climbing with sticky tape, which is available online and from local garden centers. Banding is most effective against nymphs in the spring, but homeowners have had success in trapping adults as well.

But sticky tape has trapped birds and small mammals as well. That can be avoided by caging the sticky tape with wire or fencing material wrapped around the tree.

Remove tree-of-heaven (Ailanthus altissima), a non-native, invasive plant common in landscape plantings and disturbed areas, such as along the sides of roads. Its a preferred host plant of the spotted lanternfly.

Attack the insects with pesticides. The extension website advises, Only use insecticides that are registered by the Environmental Protection Agency to treat any insect on your property. All EPA-registered insecticides have an EPA registration number and a label for appropriate and legal use. Home remedies should not be used against spotted lanternfly because they may be unsafe to humans, pets and plants, and could be illegal.

The extension website discusses a range of pesticides, including some natural materials.

Thanks for visiting PennLive. Quality local journalism has never been more important. We need your support. Not a subscriber yet? Please consider supporting our work.

See the original post:

If you see a spotted lanternfly, kill it - PennLive.com

Surgical Rejuvenation Market Report, History and Forecast 2019-2027, Breakdown Data by Manufacturers, Key Regions, Types and Application – The Market…

Surgical Rejuvenation Market: Overview

Surgical rejuvenation is a medical method focused on the practical reversal of the aging process or repair of impaired tissue with new tissue. Aging is a assembling of impairment to macromolecules, cells, tissues and organs. If any of that damage can be fixed, the outcome is rejuvenation. Rejuvenation is one of the life extension strategies. Surgical methods for rejuvenation are generally performed for face, skin, vagina, eye, hand.

Facial rejuvenationis a non-invasive or minimally invasive cosmetictreatment(often accomplished over numerous sessions). The treatment aims to re-establish skin elasticity and help preserve a youthful presence on the face and neck region.Facial rejuvenationprocedures are performed by beauty clinics, hospitals and full-service spas. The process is supported by the supervision of a dermatologist and plastic surgeons.

Vaginal rejuvenation generally incorporates vaginoplasty i.e., tightening of the vagina and/or labiaplasty or vulvaplasty. Vulvaplasty is restructuring of the vulva or labia, the outer and inner lips of the vagina. It has become a progressively common option for women. For individuals who wish recon touring after childbirth, substantial weight loss, elderly or grievance to genital structures, vaginal rejuvenation offers increased self-confidence and comfort. Conditions that can be treated withskin rejuvenation are wrinkles, pigmentation, scars, vascular conditions and vascular conditions.

Microneedling therapy or collagen induction therapy (CIT), and percutaneous collagen induction (PCI), are minimally invasive skin-rejuvenation techniques that includes the use of a device that comprises fine needles.

Browse more detail information about this report visit at at https://www.transparencymarketresearch.com/surgical-rejuvenation-market.html

The market for surgical rejuvenation can be segmented on the basis of Type Facial rejuvenation Facelift Eyelid Lift Facial Implants Neck Lift Brow Lift Vaginal rejuvenation Vaginoplasty Labiaplasty Skin rejuvenation Laser Resurfacing Botox Filler Treatments Aesthetic Others End Users Hospitals Clinics Others

Surgical Rejuvenation Market: Growth Enablers

Early appearance of elderly and increasing adoption of less painful minimally invasive rejuvenation techniques are major aspects driving the growth of the global surgical rejuvenation market. Other trends include easier access to treatments, rising affordability, growing awareness about new innovative and less painful techniques, deeper penetration of beauty merchandises in the local markets, demand for faster results and shorter treatment duration preferred by patients.However, the lack of standardized regulations is leading to an arrival of many local companies in both the developed and developing regions. Furthermore, the absence of documented and approved product effectiveness is also hampering the growth of this market.

Surgical Rejuvenation Market: Regional Insight

Geographically, the global surgical rejuvenation market is segmented into five major regions: North America, Europe, Asia-Pacific, Latin America, and Rest of the World (RoW). North America followed by Europe accounted for the major market share for surgical rejuvenation due to the technical developments in the medicine and surgery field. These developments have enabled surgeries to be non-invasive and less painful.As the financial condition of developing countries has gradually improved, the disposable income in the hands of citizens has also improved drastically in recent years. This has led to a rise in the expenditure on luxuries such as facial rejuvenation.

The growing complexity of surgical rejuvenation procedures, which has led to the development of pain-free and effective non-surgical techniques, is expected to hamper the demand for surgical rejuvenation. Asia Pacific, followed by Latin America are expected to exhibit the highest growth rate due to rising development, increase in disposable income, growing healthcare industry and the presence of a large patient population in these regions. However, unfavorable reimbursement scenario and increasing cost of surgical procedures are some of the factors that might hinder the growth of surgical rejuvenation market.

Request For Custom Research At https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=12962&source=atm

Surgical Rejuvenation Market: Key Players

Some of the key players in the surgical rejuvenation market are: Merz GmbH & Co. KGaA, Lumenis, Mentor Worldwide LLC, Cynosure, Inc., Gal derma S/A, Alma Lasers, and Strax Rejuvenation.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on: Market segments and sub-segments Market trends and dynamics Supply and demand Market size Current trends/opportunities/challenges Competitive landscape Technological breakthroughs Value chain and stakeholder analysis

The regional analysis covers: North America (U.S. and Canada) Latin America (Mexico, Brazil, Peru, Chile, and others) Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, Luxembourg) Eastern Europe (Poland, Russia) Asia Pacific (China, India, Japan, ASEAN, Australia and New Zealand) Middle East and Africa (GCC, Southern Africa, North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industrys value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report: A complete backdrop analysis, which includes an assessment of the parent market Important changes in market dynamics Market segmentation up to the second or third level Historical, current, and projected size of the market from the standpoint of both value and volume Reporting and evaluation of recent industry developments Market shares and strategies of key players Emerging niche segments and regional markets An objective assessment of the trajectory of the market Recommendations to companies for strengthening their foothold in the market

Note:Although care has been taken to maintain the highest levels of accuracy in TMRs reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Request for TOC of This Report visit at https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=12962&source=atm

See the original post here:

Surgical Rejuvenation Market Report, History and Forecast 2019-2027, Breakdown Data by Manufacturers, Key Regions, Types and Application - The Market...

Bank of Nova Scotia Acquires 8,668 Shares of Sealed Air Corp (NYSE:SEE) – TechNewsObserver

Bank of Nova Scotia lifted its stake in shares of Sealed Air Corp (NYSE:SEE) by 7.2% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 128,998 shares of the industrial products companys stock after purchasing an additional 8,668 shares during the quarter. Bank of Nova Scotia owned 0.08% of Sealed Air worth $5,519,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Motco bought a new stake in shares of Sealed Air during the 2nd quarter valued at $29,000. Thor Advisors LLC bought a new stake in shares of Sealed Air during the 1st quarter valued at $78,000. Rockefeller Capital Management L.P. bought a new stake in shares of Sealed Air during the 1st quarter valued at $88,000. NumerixS Investment Technologies Inc bought a new stake in shares of Sealed Air during the 1st quarter valued at $90,000. Finally, Northwestern Mutual Wealth Management Co. raised its stake in shares of Sealed Air by 88.0% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 2,216 shares of the industrial products companys stock valued at $102,000 after purchasing an additional 1,037 shares during the period. Institutional investors own 96.58% of the companys stock.

Sealed Air stock opened at $41.26 on Friday. Sealed Air Corp has a 52 week low of $30.22 and a 52 week high of $47.13. The business has a 50-day simple moving average of $41.93 and a 200 day simple moving average of $43.59. The stock has a market cap of $6.38 billion, a price-to-earnings ratio of 16.50, a PEG ratio of 1.46 and a beta of 1.08.

Sealed Air (NYSE:SEE) last posted its earnings results on Friday, August 2nd. The industrial products company reported $0.80 EPS for the quarter, topping the Thomson Reuters consensus estimate of $0.64 by $0.16. Sealed Air had a negative return on equity of 121.14% and a net margin of 7.84%. The business had revenue of $1.16 billion during the quarter, compared to analysts expectations of $1.17 billion. During the same period in the previous year, the business earned $0.64 earnings per share. The firms revenue was up .5% on a year-over-year basis. Equities research analysts predict that Sealed Air Corp will post 2.78 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, September 20th. Investors of record on Friday, September 6th were given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 1.55%. The ex-dividend date was Thursday, September 5th. Sealed Airs payout ratio is 25.60%.

A number of analysts recently issued reports on the company. ValuEngine lowered Sealed Air from a hold rating to a sell rating in a research note on Wednesday, September 4th. Wells Fargo & Co boosted their price objective on Sealed Air from $42.00 to $43.00 and gave the company a market perform rating in a research note on Tuesday, August 6th. Bank of America lowered Sealed Air from a buy rating to a neutral rating and set a $41.63 price objective on the stock. in a research note on Friday, June 21st. Finally, KeyCorp reiterated a sell rating and set a $39.00 price objective on shares of Sealed Air in a research note on Friday, August 2nd. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company. Sealed Air presently has an average rating of Hold and an average price target of $42.69.

Sealed Air Company Profile

Sealed Air Corporation provides food safety and security, and product protection solutions worldwide. It operates in two segments, Food Care and Product Care. The Food Care segment offers integrated packaging materials and equipment solutions to provide food safety, shelf life extension, and total cost optimization for perishable food processors in the fresh red meat, smoked and processed meats, poultry, and dairy markets under the Cryovac, Cryovac Grip & Tear, Cryovac Darfresh, Cryovac Mirabella, Simple Steps, and Optidure brands.

Further Reading: Return on Investment (ROI)

Receive News & Ratings for Sealed Air Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sealed Air and related companies with MarketBeat.com's FREE daily email newsletter.

Go here to read the rest:

Bank of Nova Scotia Acquires 8,668 Shares of Sealed Air Corp (NYSE:SEE) - TechNewsObserver

F&B players get insights on how to innovate – The Business Times

Mon, Sep 16, 2019 - 5:50 AM

Singapore

SMEs in the food and beverage sector keen to learn how to innovate can look forward to an Oct 1 event at the Food Innovation & Resource Centre (FIRC) at Singapore Polytechnic (SP).

The event, organised by The Business Times in collaboration with The Future Economy Council, will showcase ways the FIRC can help SMEs in their quest for better products, more efficient processes and product acceptance to grow their business.

Launched in 2007, the FIRC has eight labs and provides four main services: consultancy, training, lab testing and the leasing of equipment.

Consultancy refers to professional services from fulltime professionals with expertise in food science and technology, nutrition, automation and more to help solve specific product or process challenges faced.

SMEs can gain a business edge by working with the FIRC on specific issues related to their products and process development, including packaging and shelf life extension, sensory and consumer studies, and smart automation.

For example, in learning how to extend the shelf life of their products, SMEs are better placed to explore opportunities to sell these products overseas.

The FIRC also has dedicated training facilities offering generic, certified and customised training courses including those for food safety, food hygiene and packaging technology.

The centre can assist with conducting pilot trials and has an extensive range of equipment for lease which can be used to manufacture products for test marketing purposes.

So far, the FIRC has completed more than 1,500 consultancy projects and technical services, trained over 5,000 adult learners, and worked with more than 700 food establishments achieving a commendable commercialisation rate of 38 per cent.

Asked about the costs related when collaborating with FIRC, Koh Kok Sin, centre director of FIRC, said: "The charges of each project vary depending on the type of services needed, and are based on cost recovery of the expected man-hours and materials that will be spent on the project."

Kelly Koh, manager at All The Batter, which touts itself as "Singapore's first avocado-themed cafe", said: "It would be indeed useful to find out how the Food Innovation & Resource Centre can help to improve our business. We would be interested to find out how to extend the shelf life of our fresh foods made without preservatives."

The Oct 1 event, which includes a tour of the facilities, is being held at Level 5 of Singapore Polytechnic's Block T11C at 500 Dover Road from 3 to 5.30 pm.

Chee Hong Tat, Senior Minister of State for Trade & Industry, will be engaging participants in a dialogue to discuss key areas of concern in the food and beverage businesses.

Participants will hear firsthand accounts from F&B business owners who have worked with the FIRC, and learn how the collaboration has helped to fuel growth for their business.

Link:

F&B players get insights on how to innovate - The Business Times

Sealed Air Corp (NYSE:SEE) Shares Sold by US Bancorp DE – TechNewsObserver

US Bancorp DE trimmed its holdings in Sealed Air Corp (NYSE:SEE) by 10.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 51,660 shares of the industrial products companys stock after selling 6,183 shares during the period. US Bancorp DEs holdings in Sealed Air were worth $2,210,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Bank of Nova Scotia boosted its stake in Sealed Air by 7.2% in the 2nd quarter. Bank of Nova Scotia now owns 128,998 shares of the industrial products companys stock worth $5,519,000 after buying an additional 8,668 shares during the last quarter. APG Asset Management N.V. boosted its stake in Sealed Air by 173.0% in the 2nd quarter. APG Asset Management N.V. now owns 829,152 shares of the industrial products companys stock worth $31,148,000 after buying an additional 525,381 shares during the last quarter. Parametric Portfolio Associates LLC boosted its stake in Sealed Air by 8.1% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 645,814 shares of the industrial products companys stock worth $27,628,000 after buying an additional 48,510 shares during the last quarter. MML Investors Services LLC boosted its stake in Sealed Air by 3.3% in the 2nd quarter. MML Investors Services LLC now owns 11,530 shares of the industrial products companys stock worth $493,000 after buying an additional 365 shares during the last quarter. Finally, Toronto Dominion Bank boosted its stake in Sealed Air by 24.7% in the 2nd quarter. Toronto Dominion Bank now owns 126,412 shares of the industrial products companys stock worth $5,406,000 after buying an additional 25,030 shares during the last quarter. 96.58% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts have recently weighed in on SEE shares. KeyCorp reaffirmed a sell rating and issued a $39.00 price objective on shares of Sealed Air in a research note on Friday, August 2nd. Bank of America lowered Sealed Air from a buy rating to a neutral rating and set a $41.63 price objective on the stock. in a research note on Friday, June 21st. Wells Fargo & Co lifted their price objective on Sealed Air from $42.00 to $43.00 and gave the company a market perform rating in a research note on Tuesday, August 6th. Finally, ValuEngine lowered Sealed Air from a hold rating to a sell rating in a research note on Wednesday, September 4th. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company. The company has a consensus rating of Hold and a consensus price target of $42.69.

NYSE SEE opened at $41.26 on Friday. The firm has a market capitalization of $6.38 billion, a P/E ratio of 15.02, a P/E/G ratio of 1.46 and a beta of 1.08. Sealed Air Corp has a 1-year low of $30.22 and a 1-year high of $47.13. The businesss 50-day simple moving average is $41.93 and its 200-day simple moving average is $43.59.

Sealed Air (NYSE:SEE) last released its quarterly earnings data on Friday, August 2nd. The industrial products company reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.16. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.17 billion. Sealed Air had a negative return on equity of 121.14% and a net margin of 7.84%. The companys revenue was up .5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.64 EPS. On average, equities analysts expect that Sealed Air Corp will post 2.78 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, September 20th. Investors of record on Friday, September 6th were given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 1.55%. The ex-dividend date was Thursday, September 5th. Sealed Airs dividend payout ratio (DPR) is presently 25.60%.

Sealed Air Profile

Sealed Air Corporation provides food safety and security, and product protection solutions worldwide. It operates in two segments, Food Care and Product Care. The Food Care segment offers integrated packaging materials and equipment solutions to provide food safety, shelf life extension, and total cost optimization for perishable food processors in the fresh red meat, smoked and processed meats, poultry, and dairy markets under the Cryovac, Cryovac Grip & Tear, Cryovac Darfresh, Cryovac Mirabella, Simple Steps, and Optidure brands.

See Also: Are FAANG stocks a good investment?

Want to see what other hedge funds are holding SEE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sealed Air Corp (NYSE:SEE).

Receive News & Ratings for Sealed Air Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sealed Air and related companies with MarketBeat.com's FREE daily email newsletter.

Read the original post:

Sealed Air Corp (NYSE:SEE) Shares Sold by US Bancorp DE - TechNewsObserver

Kim Kardashian Shares Pic Of ‘Extremely Bad’ Psoriasis On Her Face – HuffPost

Kim Kardashian got candid about her battle with psoriasis and dealing with her new psoriatic arthritis diagnosis in a revealing personal essay for sister Kourtney Kardashians wellness site,Poosh.

The reality star spoke about her first outbreak at 25 and detailed the rollercoaster of emotions shes faced in dealing with the chronic skin condition. Kardashian said that shes learned to deal with the patch of skin her right leg that gets the most frequent flare-ups, though it often spreads.

Earlier this year is when it got extremely bad it covered my whole face and a majority of my entire body, she wrote. She also spoke about finding out she suffered from psoriatic arthritis after waking up and not being able to use her hands.

One night, I woke up to use the restroom and I physically couldnt pick up my phone. I thought it was strange but maybe I just slept on my hands weird and I was so tired, I didnt need to be checking my phone at that hour anyway. I fell right back asleep, she said in her essay. I woke up that morning and I still couldnt pick up my phone. I was freaking out I couldnt even pick up a toothbrush, my hands hurt so badly.

At a certain press event, her pain level was so high that she couldnt even get dressed.

I couldnt even get my bra on that day, and I had to have someone dress me because the pain was so unbearable, she said. With the boots I was wearing, my ankles started to feel it in those joints. Thats when I knew it wasnt just an issue in my hands, it was a bone problem.

Kardashian finally sought help and went to the doctor, where she tested positive for rheumatoid arthritis and lupus, which turned out to be a false positive. But it did lead to her diagnosis of psoriatic arthritis.

Its similar to arthritis that can stem from psoriasis and it can come and go. Its still painful and scary, but I was happy to have a diagnosis, she shared.

Kim Kardashian/InstagramKardashian shared a candid photo of her skin condition in March.

These days, Kardashian maintains a plant-based diet and said that shes extremely comfortable with her skin condition.

No matter where it is on my body, sometimes I am fine with showing it off and other times I dont want it to be a distraction, so I cover it up withbody makeup, she said, before signing off with an encouraging message for anyone else struggling with psoriasis.

You cant let it ruin your life or get the best of you. You have to do what you can to make sure you are comfortable but not let it take over, Kardashian said.

Head to Poosh to read more of Kardashians piece.

REAL LIFE. REAL NEWS. REAL VOICES.

Help us tell more of the stories that matter from voices that too often remain unheard.

Read this article:

Kim Kardashian Shares Pic Of 'Extremely Bad' Psoriasis On Her Face - HuffPost

Early Levels of Ustekinumab May Predict Longer-term Response in Patients With Psoriasis – AJMC.com Managed Markets Network

Measurement of drug levels early in treatment with ustekinumab for patients with psoriasis may be able to successfully predict patient response and, therefore, direct a treatment strategy.

The study included 491 British adults with psoriasis who were recruited from the multicenter Biomarkers of Systemic Treatment Outcomes in Psoriasis study as part of the British Association of Dermatologists Biologic and Immunomodulators Register. A total of 853 samples were obtained from the start of treatment.

The researchers measured disease activity using the Psoriasis Area and Severity Index (PASI) score. At least 1 PASI score was collected within the first year of treatment.

Early measured drug levels had a statistically significant association with 6-month response. Within 12 weeks after starting treatment, measured drug levels were associated with PASI75 (75% reduction in PASI score from baseline) 6 months after treatment started. The researchers reported that drug immunogenicity was low, with antidrug antibodies only detected in 17 (3.5%) of the patients.

This finding suggests that adequate drug exposure early in the treatment cycle may be particularly important in determining clinical outcome with ustekinumab, the authors wrote. They did suggest that additional research should focus on pharmacokinetic-pharmacodynamic modeling of the whole time course of response to ustekinumab.

In addition, they noted that further research is needed to confirm the use of therapeutic drug monitoring for ustekinumab.

In an accompanying editorial,2 Andrew Blauvelt, MD, MBA, of Oregon Medical Research Center, pointed out that although there are newer biologics available for psoriasis, there are a subset of patients who do well on older biologics and nonbiologic therapeutic options. The importance of this new study is that it helps identify which patients will respond to older and less expensive therapeutic options.

The results also bring us 1 step closer toward personalized medicine, an ideal type of future medical practice where all therapies would be chosen based on characteristics (eg, genetic, demographic, biologic) unique to a given individual patient, he wrote.Personalized medicine could assure that each chosen medication is tailored for a given patient, thus optimizing chances for therapeutic success.

References

1. Tsakok T, Wilson N, Dand N, et al. Association of serum ustekinumab levels with clinical response in psoriasis [published online September 18, 2019]. JAMA Dermatol. doi: 10.1001/jamadermatol.2019.1783.

2. Blauvelt A. Predicting clinical responses to ustekinumab: progress toward a future of personalized medicine [published online September 18, 2019]. JAMA Dermatol. doi: 10.1001/jamadermatol.2019.2587.

See the original post here:

Early Levels of Ustekinumab May Predict Longer-term Response in Patients With Psoriasis - AJMC.com Managed Markets Network

Kim Kardashian Published an 1000-Word Essay About Her Psoriasis for Poosh – Allure Magazine

Kim Kardashian has always been pretty open about living with psoriasis, but in a recent essay she penned for sister Kourtney's lifestyle site, Poosh, she got more real than ever about her journey with the condition.

In the 1000-word article, the 38-year-old mom of four detailed the highs and lows of living with the common skin condition, which she's had for 13 years now. She also shared never-before-seen photos of her psoriasis, including a flare-up on her face. Despite watching her mom, Kris Jenner, struggle with psoriasis growing up, she admitted that she ultimately had no idea what she was in for.

Turns out, her experience has been quite different than Jenner's. "She had it in her scalp and all over her body, and Id see it all the time and remember her going to the tanning salon to try and ease it for me, however, that remedy would burn the areas and cause them to itch, so I always felt helpless," she wrote. "I am the only child my mom passed down her autoimmune issue to. Lucky me, lol," she added.

Kardashian was 25 when she experienced her first psoriasis flare-up, but at the time, she had it treated with a shot of cortisone and it went away for roughly five years. When it came back in her early 30s, it did so with vengeance, and despite trying myriad remedies (i.e. celery juice, countless creams, changing her diet), she said she now just deals with the largely unpredictable flare-ups. "I have learned to live with this spot (on my leg) without using any creams or medication I just deal. Sometimes I cover it up and sometimes I dont. It doesnt really bother me," the Keeping Up With the Kardashian's star wrote.

What's more, she revealed that both times she was pregnant, it went away completely, though it was short-lived. "That was amazing, but then it came back again," she said. "Earlier this year is when it got extremely bad it covered my whole face and a majority of my entire body."

The KKW Beauty founder also shared several photos of her psoriasis in different stages, including what it looks like when it's fully flaring, as well as how it presents when it's healing. No matter what stage it's in, though, Kardashian has come to terms with it: "Ive become extremely comfortable with my psoriasis. No matter where it is on my body, sometimes I am fine with showing it off and other times I dont want it to be a distraction, so I cover it up with body makeup," she explained.

Follow this link:

Kim Kardashian Published an 1000-Word Essay About Her Psoriasis for Poosh - Allure Magazine

Kim Kardashian details her struggle with psoriasis – Page Six

Kim Kardashians troubles are more than just skin-deep.

The reality TV star turned business mogul has written a heartfelt essay for Poosh.com in which she expands on her struggle with psoriasis and psoriatic arthritis.

Even though I always grew up with my mom having psoriasis and hearing her talk about her struggle, I really had no idea what my life would be like dealing with an autoimmune disease myself, she begins, explaining that its been 13 years since she first experienced a psoriasis flare-up. I am the only child my mom passed down her autoimmune issue to, she adds. Lucky me, lol.

According to the National Psoriasis Foundation, more than 8 million Americans suffer from the condition.

Kardashian, 38, treated her first psoriasis flare-up with a cortisone shot, conveniently delivered by her then-neighbor, a dermatologist, after which it went away for five years, only to return in her early 30s.

For the past eight years, although the spots are unpredictable, I can always count on my main spot on my right lower leg, which consistently stays flared up, she details, before adding that when I got pregnant both times, it fully went away.

Kardashian described her initial experience with the arthritis side of the disease as first occurring when she was unable to pick up her phone or use a toothbrush. At first she assumed that shed simply overdone a workout, but as the day wore on, I got a bit more movement in my hands, but they really hurt from the inside I felt it in my bones.

I immediately started to cry and felt so lost, Kardashian added, noting soon after she was diagnosed with rheumatoid arthritis and lupus. Her doctor, however, explained that it was possible shed had a false positive, so she came back three days later to discover this was indeed true, and that her pain stemmed from psoriatic arthritis.

Kardashian also outlined about four months before the arthritis diagnosis where she tried everything natural every ointment, cream, serum, and foam you can possibly imagine and everything from the dermatologist, including celery juice and herbal tea.

Today, however, she has become extremely comfortable with my psoriasis.

If you have psoriasis, you cant let it ruin your life or get the best of you. You have to do what you can to make sure you are comfortable but not let it take over I hope my story can help anyone else with an autoimmune disease feel confident that there is light at the end of the tunnel.

Read this article:

Kim Kardashian details her struggle with psoriasis - Page Six

Womans psoriasis is worst docs have seen as scaly plaques cover 90% of her body – New York Post

A young mom has been forced to give up work due to the unbearable pain caused by her psoriasis.

Sabrina Speaks, 23, has scaly plaques covering 90 per cent of her body, after developing the same skin condition as Kim Kardashian.

And now Speaks is opening up about her battle with psoriasis in a bid to raise awareness of the crippling autoimmune condition.

In particular, the mother-of-two, from North Carolina, has admitted that her family and motherhood has saved her from complete depression.

Psoriasis has affected my entire life. It is an autoimmune disorder. I want to make more people aware of that, she said.

Basically, it doesnt allow my immune system to work in a way that it should.

I produce skin cells way too quickly and I also have psoriatic arthritis which is an arthritis that ties in with psoriasis in the most severe cases.

The main side effects of my condition are fatigue, pain, swelling, itching, burning, depression and anxiety.

I cant work because of the pain it causes and also the reactions that I get from people seeing it.

While psoriasis isnt a rare condition, the severity of Speaks psoriasis is extreme with docs saying she is one of the worst cases they have seen.

A lot of people have it. It can be brought on by many things. Stress or even a simple cold can start your symptoms straight away, she said.

But a lot of people do not have it as severe as I do, where a lot of treatments dont work.

Heath Franklin / Barcroft Media

Heath Franklin / Barcroft Media

Barcroft Media

Barcroft Media

Barcroft Media

Heath Franklin / Barcroft Media

I am 90 percent or more covered in plaques. Im clearing up a bit now Im taking my injections, but prior to this, I was way more covered from head to toe.

According to my doctor, I am one of the worst cases theyve ever seen.

The hardest part about living with it is how it affects me as a person, how it changes me.

Im unable to be the person I want to be. I want to be running around with my children and doing things in the world without getting stared at, or without feeling pain.

Unfortunately, I just cant.

There is currently no cure for psoriasis, but Sabrina is having injections on a treatment plan to try and ease the pain and the number of plaques she has.

It all started out as just one spot on the back of her head a spot that suddenly turned really itchy and into a crusty patch.

It kept getting worse and worse. At first doctors said it was ringworm, but eventually, we found out it was psoriasis, Speaks added.

In my teenage years, making friends was really hard. A lot of people were like whos that girl that has all that stuff on her skin and why is she always tired? Just so many questions. I endured way too much bullying as a child and teenager.

And as well as the physical pain, Sabrina has a tricky time when out in public and tries her best to cope with the stares and pointing.

Adults are definitely more harsh than children. Children will come up and ask me about it. Whereas adults will just whisper, point, give you dirty looks and stares, she said.

They dont bother to just ask. Its really hurtful. I hope that with certain people reading and watching my story, they wont be that person in the future. To not just me, but to anyone living with a disease or illness.

Despite her crippling pain, Speaks has managed to find happiness in the shape of her husband and two daughters, Sophia and Madison.

My babies are my life, she said.

If Im anything in this world, Im a mother. Thats what I am first and what Ive always wanted to be.

On a daily basis, they drive me bonkers. But they have also improved my condition.

They make me happier, they take a lot of stress away too.

The turning point in my life was definitely having my first daughter, Sophia. The moment I saw her, I knew I had to be more confident for her sake.

Whether that meant me suffering or not.

And Speaks husband, Daniel, 28, added: I would describe Sabrina as a beautiful, loving mother and wife that would do anything for anybody.

Shes got a heart of gold.

When we first met, she told me about her condition. I was just like youre a really nice person and I want to get to you know you better I didnt mind it. We clicked right away.

I try to take good care of her when shes sick. She struggles a lot sometimes, I so want to make sure Im there for her.

Speaks is now focusing her attention on raising more awareness for psoriasis and those who live with similar conditions.

Its so important to raise awareness for this because theres just not enough information out there, she added.

Were tired, were exhausted, were in pain its a lot to handle. I am proud of everything I am trying to do in my life now, despite my condition. I have a loving husband and two wonderful children, so what more could I want?

View post:

Womans psoriasis is worst docs have seen as scaly plaques cover 90% of her body - New York Post

Kim Kardashian Was Diagnosed With Psoriatic Arthritis After Her Lupus Scare On ‘KUWTK’ – Women’s Health

Axelle/Bauer-GriffinGetty Images

Kim Kardashian's health woes have been a major plot line for the new season of Keeping Up With The Kardashians. On last week's episode, Kim underwent testing for lupus and rheumatoid arthritis antibodies after she said she'd been experiencing numbness in her hands and other symptoms, and tested positive.

Ive been feeling so tired, so nauseous and my hands are really getting swollen, she said. I feel like I literally am falling apart. My hands are numb. Lately, my wrists are starting to hurt again but its definitely a different feeling, she said. I feel this in my bones. Its starting to really worry me. I really have to look into this. Based on the symptoms, it looks like I have rheumatoid arthritis. Its so scary. So I have to go to the doctor and see whats going on because I cant live like this.

But she still didn't have exact answers for what was going on. On last night's episode of KUWTK, Kim finally learned what was causing her pain.

In the episode, she went to a doctor and had an ultrasound done on her hands to determine whether or not she was suffering from lupus or rheumatoid arthritis. And it turns out, she was diagnosed with psoriatic arthritis.

First of all, if you have any evidence for lupus, we would have screened it, the doctor explained. You do not have lupus and rheumatoid arthritis. So, you can be reassured. You probably have psoriatic arthritis because psoriasis comes and goes. Theres nothing there right now.

Kim immediately let out a deep breath after hearing the news. Im so relieved that this is just psoriatic arthritis, Kim admitted. The pain is going to come and go sometimes, but I can manage it and this isnt going to stop me.

According to the American College of Rheumatology, psoriatic arthritis is a form of inflammatory arthritis that happens to people with psoriasis. Kim's been open about her struggles with the skin condition psoriasis in the past.

The main symptoms of psoriatic arthritis are painful, stiff and swollen joints. While the cause of psoriatic arthritis is not known, of those with psoriatic arthritis, 40 percent also have a family member with psoriasis or arthritis, according to the American College of Rheumatology.

It's not unusual for someone Kim's age to be diagnosed with psoriatic arthritispeople between 30 and 50 years old are the most likely to be diagnosed, per the American College of Rheumatology. And while there is no cure for psoriatic psoriasis, treatments usually involve over-the-counter anti-inflammatories or prescription anti-rheumatic drugs.

Here's hoping Kim finds a resolution to her symptoms soon.

Follow this link:

Kim Kardashian Was Diagnosed With Psoriatic Arthritis After Her Lupus Scare On 'KUWTK' - Women's Health

Psoriasis Drug Target Holds Potential for Bone Cancer – Technology Networks

Using a mouse model, researchers have discovered a potential therapeutic target for osteosarcoma one which is already used to treat psoriasis. These new findings are published in Cancer Discovery.

Not just "growing pains"

Osteosarcoma is a type of bone cancer, commonly diagnosed in young people; around half of new cases in the United States each year are in children and teenagers. As such, the signs and symptoms can often be mistaken for "growing pains", which can delay diagnosis. If, by this point, the cancer has spread outside the bone, five-year survival rates decrease from 77% to 65%.

Current treatment for osteosarcoma follows a standard pattern; surgery, chemotherapy and/or radiotherapy. Given the survival rate, there are efforts to develop treatments beyond this standard. One such treatment is immunotherapy, which is rapidly becoming the fifth pillar of cancer treatment.1

The role of the immune system

Researchers were led towards immune molecules by the results of genome-wide association studies (GWAS), which associated the gene GRM4 with susceptibility to osteosarcoma.2,3 It was through investigating this gene that they found an association between osteosarcoma and IL-23, a pro-inflammatory molecule within the immune system.

In a recent press release, lead author Maya Kansara says : "In a mouse model of osteosarcoma, we investigated the role of GRM4, as well as a number of immune molecules, the production of which is regulated by GRM4," she continues: "In our model, we discovered that the inflammatory molecule IL-23 was critical to osteosarcoma formation and progression."

The authors uncovered the role of IL-23 by removing it from mice, via a gene knock-out, finding that they were then protected from developing osteosarcomas. Blocking IL-23 in mice with existing osteosarcomas was also trialed the growth of these tumors was successfully suppressed.4From bench to bedside

The relationship between IL-23 and development of osteosarcoma suggests the former could be targeted in treatment of the latter. IL-23 is already a target in the treatment of some autoimmune diseases, including psoriasis.

"Drugs that block IL-23 are approved and well-tolerated, and on the market now for the treatment of psoriasis," says Professor David Thomas, co-author of the study. "We are now designing clinical trials to see whether they can provide much-needed improved health outcomes for osteosarcoma patients."

References

1.Oiseth, S.J., Aziz, M.S. (2017) Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead. Journal of Cancer Metastasis and Treatment. DOI: https://doi.org/10.20517/2394-4722.2017.41

2.Savage, S.A., et al. (2013) Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nature Genetics. DOI: https://dx.doi.org/10.1038%2Fng.2645

3.Jiang, C., et al. (2014) GRM4 gene polymorphism is associated with susceptibility and prognosis of osteosarcoma in a Chinese Han population. Medical Oncology. DOI: https://doi.org/10.1007/s12032-014-0050-4

4.Kansara, M., et al. (2019) Infiltrating myeloid cells drive osteosarcoma progression via GRM4 regulation of IL23. Cancer Discovery. DOI: https://doi.org/10.1158/2159-8290.CD-19-0154

Read more from the original source:

Psoriasis Drug Target Holds Potential for Bone Cancer - Technology Networks

High blood pressure risk in psoriasis, psoriatic arthritis – Dermatology Times

Psoriasis and psoriatic arthritis are relatively common immune mediated diseases. The increase in cardiovascular disease associated with psoriatic disease is well established. Interestingly, some studies suggest a stronger link between psoriatic arthritis and cardiovascular disease.

Hypertension is a major risk factor for the development of cardiovascular disease. It is therefore considered an important modifiable risk factor in the development of cardiovascular disease. Previous studies have shown that patients with psoriasis have an increased risk of poorly controlled hypertension. Furthermore, there appears to be an increased prevalence of hypertension in patients with psoriatic arthritis even after adjusting for traditional cardiovascular risk factors.

RELATED:Cardiovascular risk associated with psoriasis patients age, race

A group of collaborating physicians from Hospital Universitario Central de Asturias (HUCA), Spain, led by Dr. Ruben Queiro performed an observational cross-sectional study to analyze the comparative prevalence of hypertension in psoriatic disease.

The patient cohort was from a multidisciplinary (rheumatology/dermatology), single center clinic, in a university hospital in Spain. 290 patients with psoriatic arthritis and 310 patients with psoriasis (in the absence of psoriatic arthritis) were included. For the purpose of the study hypertension was defined as 140/90 on two separate days during a one month period or the chronic use of antihypertensive medication.

The study cohort was composed of 324 men and 276 women with a mean age of 5312 years. The study results showed the following: 144/600 patients had hypertension (24%). The mean age at onset of psoriasis and arthritis was significantly higher in the hypertension population (3917 in HBP vs. 2616 years in non-HBP, p<0.01, 4917 in HBP vs. 4114 years in non-HBP, p<0.01). The mean body weight and BMI were significantly higher in HBP patients (8316 in HBP vs. 7715 kg in non-HBP, p<0.01, 30.24.9 in HBP vs. 274.4 in non-HBP, p<0.01).

References:

Queiro R, Lorenzo A, Tejn P, Pardo E, Coto P. Hypertension is associated with increased age at the onset of psoriasis and a higher body mass index in psoriatic disease. Clin Rheumatol. 2019;38(8):2063-2068.

Continued here:

High blood pressure risk in psoriasis, psoriatic arthritis - Dermatology Times

Psoriasis cant be cured, but new treatments can clear skin in many – Pocono Record

Plaque psoriasis is a common skin condition that causes raised red patches covered with a silvery white buildup of dead skin cells to form. Plaque psoriasis is the most common form of psoriasis about 80 to 90% of the 7 million to 8 million Americans who have psoriasis have plaque psoriasis, according to the National Psoriasis Foundation.

Plaque psoriasis is most commonly found on the scalp, elbows, knees and lower back, but it can affect anywhere on the body, says Dr. Alan Westheim, dermatologist at St. Lukes Medical Associates of Monroe County in East Stroudsburg. The plaques can be itchy and painful, he says.

Because psoriasis can be unsightly, many fear it is contagious, but it is not, Westheim says. It cant be spread by touch or by close contact, he says. We also know that psoriasis has a large effect on the patients quality of life.

Psoriasis is an autoimmune disease, Westheim explains. That means the body sees its own cells as foreign invaders and attacks them. The attacks cause the skin to grow more quickly, Westheim says. Normal skin replenishes every five to six weeks, Westheim says. When you have psoriasis, your skin replenishes every five to six days.

It isnt known why some people get psoriasis and others dont, Westheim says. Genetics is believed to play a role. About 10% of people are born with genes that make them prone to psoriasis, but only about 3% of people get psoriasis. Obesity also appears to play a role; the greater your weight, the greater likelihood of developing psoriasis, he says.

If both parents have psoriasis, their children are more likely to get psoriasis, too, Westheim says.

You can get psoriasis at any age, even as an infant, Westheim says. However, it is most common when people are in their late teens and early 20s and again after age 60.

Topical, systemic treatments available

There is no cure for psoriasis, but it can be treated, Westheim says. Some people are able to achieve clear skin with the newer treatments available. The newer treatments are designed to stop the immune process that leads to plaques.

When it comes to treatment, theres a ladder we climb, Westheim says. We try one treatment, and if that doesnt work, we go onto the next.

Depending on the severity of your psoriasis, your doctor may recommend topical treatments topical creams and steroids and vitamin D derivatives, he says. If you respond, great. If you dont, we might try UV light treatments. And if that doesnt work, we can talk about medications.

Methotrexate had been the mainstay for many years, but now there are a number of newer drugs on the market, Westheim says. The newer medicines are biologics and work wonderfully but are costly around $20,000 a year, he says.

Treatments are important to prevent disease progression and joint destruction, he says. It is important to look at psoriasis as a systemic disease as there is associated risk for heart disease and other systemic illnesses.

About a third of people with psoriasis also develop psoriatic arthritis, which can cause joint pain and swelling, Westheim says.

View post:

Psoriasis cant be cured, but new treatments can clear skin in many - Pocono Record

Anti-psoriasis compound could lead to new drug for malaria – Futurity: Research News

Share this Article

You are free to share this article under the Attribution 4.0 International license.

Redesigning molecules originally developed to treat the skin disease psoriasis could lead to an effective new drug against malaria, according to new research.

Researchers modified a class of molecules called pantothenamides to increase their stability in humans. The new compounds stop the malaria parasite from replicating in infected humans and from being transmitted to mosquitoes. Theyre also effective against malaria parasites resistant to currently available drugs.

Malaria is a major global health concern, with around 216 million cases and 400,000 deaths annually. The deadliest form of the disease is caused by the parasite Plasmodium falciparum, which is transmitted to humans from the bite of an infected Anopheles mosquito. Because many Plasmodium parasites have developed resistance to the most common drugs used against them, there is a pressing need for effective new treatment options.

We have known for a long time that pantothenamides are extremely potent against the malaria parasite, but they become unstable within biological fluids because an enzyme clips them apart before they can act, says coauthor Manuel Llins, professor of biochemistry and molecular biology and of chemistry at Penn State. The researchers found that changing a chemical bond in a pantothenamide molecule prevents this clipping, making it viable for use as a new antimalarial drug, he says.

The team found that the modified pantothenamide molecules not only interfere with the development of the malaria parasite during its asexual growth phase in the blood but also prevent transmission of the sexual form of the parasite from human blood to mosquitoes.

By also preventing the transmission of malaria parasites from infected people into mosquitoes, these pantothenamides can reduce the chances that mosquitoes will be infectious to others, says Llins. It is currently widely accepted that next-generation antimalarial drugs must target the parasite at multiple stages to both cure the disease in an infected individual and prevent its spread to others.

Llins and Erik Allman, postdoctoral scholar at Penn State at the time of the research, investigated exactly how the four most potent molecules in the compound class kill the malaria parasite. Specifically, they examined how these compounds affect the parasites metabolism while growing in human blood.

The team discovered that, because the pantothenamide molecule closely resembles the essential vitamin B5, the parasite mistakenly takes it in and metabolizes it. This leads to the formation of molecular analogues, or antimetabolites, which decrease the parasites production of acetyl-CoA, a compound critical for its survival.

The molecule has a mechanism of action that hasnt been used before, says Koen Dechering, of TropIQ Health Sciences. This means that theres no resistance to the drug as yet, and it is effective against many forms of malaria. Because parasite resistance to malaria drugs is a major problem worldwide, we are very close to a breakthrough.

Pantothenamides have a simple chemistry, so they are easy and inexpensive to make, says Llins, And we now know their mode of action, which we dont always know before moving into drug development. This makes pantothenamides excellent candidates for further development and eventual clinical trials.

The research appears in the journal Science Translational Medicine.

Additional researchers from Penn State, Radboud University Medical Center in the Netherlands, St. Judes Childrens Research Hospital, Chiralix in the Netherlands, XenoGesis in the United Kingdom, the Swiss Tropical and Public Health Institute in Switzerland, the University of Basil in Switzerland, the Art of Discovery in Spain, Medicines for Malaria Venture in Switzerland, and Hermkens Pharma Consultancy in the Netherlands contributed to the work.

Source: Penn State

Go here to see the original:

Anti-psoriasis compound could lead to new drug for malaria - Futurity: Research News

Guselkumab Demonstrates Superiority to Secukinumab for Reducing Psoriasis Area and Severity – Dermatology Advisor

Guselkumab administered at 100 mg for 5 weeks and then every 8 weeks was superior to secukinumab at 300 mg for 5 weeks and then every 4 weeks in inducing a 90% reduction in the Psoriasis Area and Severity Index (PASI 90) response at 48-week follow-up, a phase 3 study in the Lancet suggests.

Patients aged 18 years who had moderate to severe plaque-type psoriasis were enrolled in the trial. The study was a comparator-controlled analysis conducted at 142 outpatient centers in nine countries. Only patients who were candidates for phototherapy or systemic therapy were eligible to participate. Study investigators randomly assigned patients to either 100 mg guselkumab at week 0 and week 4 and then every 8 weeks (n=534) or 300 mg secukinumab at weeks 0, 1, 2, 3, and 4, and then every 4 weeks (n=514).

The proportion of patients who achieved a 90% reduction in PASI 90 response at week 48 comprised the primary endpoint. Additional secondary endpoints included the proportion of patients who achieved a PASI 75 response at weeks 12 and 48, PASI 90 response at week 12, PASI 75 response at week 12, PASI 100 response at week 48, Investigators Global Assessment score of 0 (cleared) at 48 weeks, and Investigators Global Assessment score of 0 or 1 (minimal) at 48 weeks. In patients who received 1 dose of their assigned study drug from week 0 to week 56, safety was also assessed.

At 48 weeks, a higher proportion of patients who achieved a PASI 90 response was observed in the guselkumab group vs the secukinumab group (84% vs 70%, respectively; P <.0001). Guselkumab was noninferior to secukinumab in terms of the proportion of patients who achieved a PASI 75 response at both week 12 and week 48 (85% vs 80%, respectively; treatment difference, 4.3 percentage points; 95% CI, 0.2 to 8.9; P <.0001). The researchers were unable to establish superiority of guselkumab for PASI 75 at these time points (P =.0616). There was no difference between the groups with regard to the rate of adverse events, infections, or serious adverse events.

Limitations of the study were the lack of assessment of drug concentrations as well as the data projecting longer than 1 year.

The researchers added that blocking the regulatory capacity of the [interleukin]-23 pathway with guselkumab rather than directly targeting interleukin-17A with secukinumab might be useful for maintaining a durable response and preventing recurrence of disease in patients with psoriasis.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

Follow @DermAdvisor

Reference

Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831-839.

Read the original:

Guselkumab Demonstrates Superiority to Secukinumab for Reducing Psoriasis Area and Severity - Dermatology Advisor

Patients With Psoriasis Have 2-Fold Higher Risk of Mortality – Dermatology Advisor

In the United States, patients with psoriasis have a 2-fold higher risk for mortality compared with individuals without psoriasis, a study in the Journal of the American Academy of Dermatology suggests. The risk for mortality in these patients appears to be partially mediated by the higher prevalence of infectious, cardiovascular, and neoplastic disorders that are frequently observed in patients with psoriasis.

The ongoing, cross-sectional National Health and Nutrition Examination Survey (NHANES) was used to identify patients aged >10 years with self-reported psoriasis (n=347) and control patients without psoriasis (n=12,684). Only individuals who participated in the NHANES between 2003 and 2006, as well as 2009 and 2010, were included in the retrospective study.

Medical history questionnaires were used to assess participants comorbidities, including history of cancer, cardiovascular disease, chronic kidney disease, and diabetes mellitus. Data linked from national databases were examined to identify associated mortality rates.

The presence of psoriasis was associated with a 1.99-fold higher risk for mortality during a 52.3-month follow-up period compared with nonpsoriatic control patients (hazard ratio, 1.99; 95% CI, 1.01-3.93; P =.047), according to the adjusted analysis. Female sex and income were associated with a lower mortality risk, whereas smoking and increasing age drove the higher risk for mortality. Comorbidities that partially mediated the increased risk for mortality in patients with psoriasis included cardiovascular disease (15.5%), chronic obstructive pulmonary disease (8.7%), cancer (11.7%), diabetes mellitus (5.9%), chronic kidney disease (4.2%), and stroke (4.7%).

Limitations of the analysis include its retrospective nature, as well as the self-reported nature of some of the data.

Considering the different guidelines and use of systemic therapies between countries, the researchers wrote, future population-based studies investigating the effect of systemic therapies on mortality risk are essential for understanding the long-term effects of these medications.

Follow @DermAdvisor

Reference

Semenov YR, Herbosa CM, Rogers AT, et al. Psoriasis and mortality in the US: Data from the National Health and Nutrition Examination Survey [published online August 12, 2019]. J Am Acad Dermatol. doi:10.1016/j.jaad.2019.08.011

More here:

Patients With Psoriasis Have 2-Fold Higher Risk of Mortality - Dermatology Advisor